HuCAL developer MorphoSys has cut a discovery deal with the Moulder Center for Drug Discovery Research, allowing the Center access to the firm's Ylanthia® technology to validate new disease-related targets and produce therapeutic antibody candidates. Under the deal's terms, MorphoSys is getting an exclusive option to develop any antibodies that result from this alliance.

The Moulder Center, where the Ylanthia library will be installed, is a unit of Temple University's School of Pharmacy that is described by Temple as a multidisciplinary research hub for further development of scientific discoveries identified by the university's faculty, scientists, and external partners into novel therapies. It features a Biotherapeutics Discovery Unit dedicated to drug design and lead optimization in disease areas including cancer and Alzheimer's disease.

Temple says this deal will be a boon for its researchers. “Our new collaborative effort with MorphoSys will provide our faculty, staff, and students with the cutting-edge scientific tools necessary to identify the next generation of antibody therapeutics,” said Magid Abou-Gharbia, Ph.D., associate dean for research in Temple's School of Pharmacy and director of the Moulder Center, in a statement. 

Previous articleBMS Acquires iPierian for Up to $725M
Next articleSingle Cell Type May Open the Door to Effective Cancer Vaccines